Abstract
Nanoxel-PMTM (Nanoxel) is a docetaxel-loaded methoxy-poly(ethylene glycol)-block-poly(D,L-lactide) (mPEG-PDLLA). This newly developed and marketed nanoformulation exhibits an improved pharmacokinetic profile, efficacy, and safety. Although the safety of Nanoxel to docetaxel as well as its bioequivalence must be clinically confirmed, all biological activities have not been examined in in vitro or in vivo studies. Here, the toxicity in a cultured cell system and the effects on blood cells were tested with Nanoxel and docetaxel. The in vitro cytotoxicity of Nanoxel was found to be comparable to or slightly lower than that of docetaxel depending on the concentrations tested or the cell types. Neither docetaxel nor Nanoxel induced erythrocytes hemolysis and produced reactive oxygen species up to 100 µM. However, Nanoxel was able to enhance the aggregatory response of platelets to collagen, whereas docetaxel attenuated such aggregation in a range of 50–100 µM, while thrombin-induced aggregation was not affected by either of them. Docetaxel or Nanoxel did not alter basal level of Ca2+ and 5-hydroxytryptamine-evoked Ca2+ transient in vascular smooth muscle cells. These results suggest that the mPEG-PDLLA micellar formulation alters the toxicological properties of docetaxel, and that extra cautions are needed when evaluating the safety of nanomedicine.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Takimoto, C.H. and Beeram, M. (2008) Microtubule stabilizing agents in clinical oncology in The Role of Microtubules in Cell Biology, Neurobiology, and Oncology (Fojo, T. Ed.). Humana Press, Totowa, NJ, pp. 395–419.
Herbst, R.S. and Khuri, F.R. (2003) Mode of action of docetaxel - a basis for combination with novel anticancer agents. Cancer Treat. Rev., 29, 407–415.
Clarke, S.J. and Rivory, L.P. (1999) Clinical pharmacokinetics of docetaxel. Clin. Pharmacokinet., 36, 99–114.
Kenmotsu, H. and Tanigawara, Y. (2015) Pharmacokinetics, dynamics and toxicity of docetaxel: why the Japanese dose differs from the Western dose. Cancer Sci., 106, 497–504.
Yanasarn, N., Sloat, B.R. and Cui, Z. (2009) Nanoparticles engineered from lecithin-in-water emulsions as a potential delivery system for docetaxel. Int. J. Pharm., 379, 174–180.
Kim, G.H., Lee, J.Y., Kang, Y.M., Kang, K.N., Kim, E.S., Kim, D.Y., Kim, J.H. and Kim, M.S. (2011) Preparation and characterization of self-emulsified docetaxel. J. Nanomater., 2011, 6.
Du, W., Hong, L., Yao, T., Yang, X., He, Q., Yang, B. and Hu, Y. (2007) Synthesis and evaluation of water-soluble docetaxel prodrugs-docetaxel esters of malic acid. Bioorg. Med. Chem., 15, 6323–6330.
Naik, S., Patel, D., Surti, N. and Misra, A. (2010) Preparation of PEGylated liposomes of docetaxel using supercritical fluid technology. J. Supercrit. Fluids, 54, 110–119.
Liang, G., Jia-Bi, Z., Fei, X. and Bin, N. (2010) Preparation, characterization and pharmacokinetics of N-palmitoyl chitosan anchored docetaxel liposomes. J. Pharm. Pharmacol., 59, 661–667.
Lee, S.-W., Yun, M.-H., Jeong, S.W., In, C.-H., Kim, J.-Y., Seo, M.-H., Pai, C.-M. and Kim, S.-O. (2011) Development of docetaxel-loaded intravenous formulation, Nanoxel-PM™ using polymer-based delivery system. J. Control. Release, 155, 262–271.
Lee, M.Y., Song, H., Nakai, J., Ohkura, M., Kotlikoff, M.I., Kinsey, S.P., Golovina, V.A. and Blaustein, M.P. (2006) Local subplasma membrane Ca2+ signals detected by a tethered Ca2+ sensor. Proc. Natl. Acad. Sci. U.S.A., 103, 13232–13237.
Oh, S.-J., Kim, H., Liu, Y., Han, H.-K., Kwon, K., Chang, K.-H., Park, K., Kim, Y., Shim, K., An, S.S.A. and Lee, M.-Y. (2014) Incompatibility of silver nanoparticles with lactate dehydrogenase leakage assay for cellular viability test is attributed to protein binding and reactive oxygen species generation. Toxicol. Lett., 225, 422–432.
Liu, Y., Park, J.-M., Chang, K.-H., Huh, H.J., Lee, K. and Lee, M.-Y. (2016) AMP-activated protein kinase mediates the antiplatelet effects of the thiazolidinediones rosiglitazone and pioglitazone. Mol. Pharmacol., 89, 313–321.
Park, J.-M., Chang, K.-H., Park, K.-H., Choi, S.-J., Lee, K., Lee, J.-Y., Satoh, M., Song, S.-Y. and Lee, M.-Y. (2016) Differential effects between cigarette total particulate matter and cigarette smoke extract on blood and blood vessel. Toxicol. Res., 32, 353–358.
Park, J.-M., Lee, J.-H., Na, C.-S., Lee, D., Lee, J.-Y., Satoh, M. and Lee, M.-Y. (2016) Heartwood extract of Rhus verniciflua Stokes and its active constituent fisetin attenuate vasoconstriction through calcium-dependent mechanism in rat aorta. Biosci. Biotechnol. Biochem., 80, 493–500.
Chang, K.H., Park, J.M., Lee, C.H., Kim, B., Choi, K.C., Choi, S.J., Lee, K. and Lee, M.Y. (2017) NADPH oxidase (NOX) 1 mediates cigarette smoke-induced superoxide generation in rat vascular smooth muscle cells. Toxicol. In Vitro, 38, 49–58.
Ojima, I., Lichtenthal, B., Lee, S., Wang, C. and Wang, X. (2016) Taxane anticancer agents: a patent perspective. Expert Opin. Ther. Pat., 26, 1–20.
Huang, X.-X., Zhou, C.-L., Wang, H., Chen, C., Yu, S.-Q., Xu, Q., Zhu, Y.-Y. and Ren, Y. (2011) Pharmacokinetics, efficacy, and safety evaluation of docetaxel/hydroxypropyl-sulfobutyl-β-cyclodextrin inclusion complex. AAPS Pharm-SciTech, 12, 665–672.
Wang, Y.B., Wang, J.C., Meng, M., Zhang, H. and Zhang, Q. (2010) Preparation and evaluation of docetaxel-loaded albumin nanoparticles for intravenous administration. J. Chin. Pharm. Sci., 19, 214–222.
Engels, F.K., Mathot, R.A.A. and Verweij, J. (2007) Alternative drug formulations of docetaxel: a review. Anticancer Drugs, 18, 95–103.
Elm’hadi, C., Tanz, R., Khmamouche, M.R., Toreis, M., Mahfoud, T., Slimani, K.A., Errihani, H. and Ichou, M. (2016) Toxicities of docetaxel: original drug versus generics-a comparative study about 81 cases. SpringerPlus, 5, 732.
Fu, P.P., Xia, Q., Hwang, H.-M., Ray, P.C. and Yu, H. (2014) Mechanisms of nanotoxicity: generation of reactive oxygen species. J. Food Drug Anal., 22, 64–75.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
About this article
Cite this article
Do, V.Q., Park, KH., Park, JM. et al. Comparative In Vitro Toxicity Study of Docetaxel and Nanoxel, a Docetaxel-Loaded Micellar Formulation Using Cultured and Blood Cells. Toxicol Res. 35, 201–207 (2019). https://doi.org/10.5487/TR.2019.35.2.201
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.5487/TR.2019.35.2.201